EWTX Edgewise Therapeutics, Inc.
USHealthcareAs of 2026-08-24
Why EWTX matters now
Edgewise Therapeutics, Inc. (EWTX) is a US stock in Healthcare. The latest InvestLog snapshot shows $44.72 with +1.22% on the session and $4.81B in market capitalization; recent performance reads 1-month +17.12% and YTD +48.31%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-49.0M, and EPS of $-0.46. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.8%.
The latest indexable market news headline is "Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $52.00; recent insider activity includes Morris Arlene filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
7.99
P/S
0.00
EV/EBITDA
-22.34
DCF Value
$0.50
FCF Yield
-3.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-32.5%
ROA
-33.9%
ROIC
-40.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-49.0M | $-0.46 |
| Q4 2025 | $0.00 | $-50.2M | $-0.47 |
| FY 2025 | $0.00 | $-167.8M | $-1.63 |
| Q3 2025 | $0.00 | $-40.7M | $-0.39 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$47.56
Target (Median)
$52.00
Target Range
$25.00 - $66.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.30
Edgewise Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing small-molecule treatments for a range of musculoskeletal disorders. Its leading investigational drug, EDG-5506, is an orally administered compound specifically engineered to tackle the fundamental genetic causes of dystrophinopathies, including Duchenne and Becker muscular dystrophy. This candidate has successfully concluded its Phase 1 clinical trial. Beyond EDG-5506, Edgewise maintains a pipeline of precision medicine candidates designed to modulate key muscle proteins, thereby addressing various genetically defined muscle conditions. Established in 2017, the company is headquartered in Boulder, Colorado.